MedTrace Logo

Lidocaine Versus Esmolol for Optimizing Surgical Field Visibility

NCT04260685 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2020-07-02

No results posted yet for this study

Summary

Intra-operative blood loss is an important attribution and predictor of the lumbar spine surgery and patient outcome. Stripping the muscle off bone makes more exposed bleeding spine surface is one of causes for blood loss during lumbar surgeries. The importance to decrease the bleeding is to improve the surgical field visibility which provides technical ease for surgeon and decreases the surgical time besides maintaining the hemodynamic stability. In past, there were many trials to minimize surgical blood loss by different drugs such as Na Nitroprusside, magnesium sulfate, volatile anesthetics and beta-adrenergic antagonist.

Conditions

  • Lumbar Disc Herniation

Interventions

DRUG

Lidocaine

IV bolus of 1.5mg/kg lidocaine 1% followed by continuous infusion of 1.5mg/kg/h

DRUG

Esmolol

IV bolus of esmolol 0.5 mg/kg followed by continuous infusion of 100-300 ug/kg/min

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Principal Investigators

  • Olfat Ibrahem Amin, M.D · Zagazig University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-04
Primary Completion
2020-06-15
Completion
2020-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04260685 on ClinicalTrials.gov